6 completed, 2 terminated, 1 withdrawn. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Withdrawn 1 |
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
Follow Recurrent Primary Peritoneal Cavity Cancer: new trials by email Literature Review of Recurrent Primary Peritoneal Cavity Cancer trials Research Report on Recurrent Primary Peritoneal Cavity Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, IDO1 inhibitor INCB024360, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-12-01 | 2013-12-18 | |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer paclitaxel, ganetespib, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 12 | 2013-10-09 | 2024-03-26 |
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin SJG-136, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 19 | 2010-07-01 | 2015-05-25 |
| Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer sunitinib malate, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2007-01-01 | 2015-01-27 |
| Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer cediranib maleate, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 74 | 2006-04-01 | 2018-08-29 |
| Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer gemcitabine hydrochloride, sorafenib tosylate, laboratory biomarker analysis - Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 33 | 2004-09-01 | 2013-06-13 |
| Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer cisplatin, alvocidib, cisplatin/flavopiridol - Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2004-04-01 | 2014-05-21 |
| Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer fenretinide, laboratory biomarker analysis, pharmacological study - Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2001-09-01 | 2013-03-25 |
Carcinoma, Ovarian Epithelial (9) · Fallopian Tube Neoplasms (6) · Brenner Tumor (1) · Pleural Effusion, Malignant (1)
Adnexal Diseases (9) · Carcinoma (9) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases (9) · Genital Diseases, Female (9) · Genital Neoplasms, Female (9) · Gonadal Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Ovarian Diseases (9)
1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) (1) · Cisplatin (1) · Drug Therapy (1) · Fenretinide (1) · Gemcitabine (1) · Metformin (1) · Paclitaxel (1) · STA 9090 (1) · Sorafenib (1) · Sunitinib (1) · Taxes (1) · alvocidib (1) · cediranib (1) · epacadostat (1)
National Cancer Institute (NCI) (6) · Fox Chase Cancer Center (1) · Roswell Park Cancer Institute (1) · University of Chicago (1)
United States (6) · Canada (3)
Agustin Garcia (1) · Amit Oza (1) · Gina Martina-Smaldone, MD (1) · Holger Hirte (1) · James Biagi (1) · Keith Bible (1) · Kunle Odunsi (1) · Marta Crispens (1) · Seiko Yamada (1)
N01CM62203 (2), N01CM00100 (1), N01CM17101 (1), N01CM62201 (1), N01CM62205 (1), N01CM62209 (1), P30CA006927 (1), P30CA015083 (1), P30CA016056 (1)